ANGPTL3 drugs for Homozygous Familial Hypercholesterolemia

2 tracked ANGPTL3 drugs in the Homozygous Familial Hypercholesterolemia race. The class explanation lives on the ANGPTL3 page; the full indication pipeline across every mechanism is on the Homozygous Familial Hypercholesterolemia page.

1 approved / phase 41 Phase 3

Head-to-head evidence: Evinacumab vs SHR-1918

The roster

← all ANGPTL3 drugs